GLP1R and cancer: While meta-analyses of randomised trials have generated point estimates >1, the confidence intervals have been wide owing to limited sample size and short follow-up time, which limits the assessment of rare cancer events.4, 5 The largest meta-analysis was based on 43 124 patients exposed to GLP1 receptor agonists in trials with a median duration of only 75 weeks, and the confidence interval was consistent with up to twofold increase in risk.